http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : John B. Liao (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Jovana Y. Martin,Renata R. Urban,John B. Liao,Barbara A. Goff 대한부인종양학회 2016 Journal of Gynecologic Oncology Vol.27 No.5
Objective: Bevacizumab was recently approved by the US Food and Drug Administration foruse in recurrent platinum resistant epithelial ovarian cancer (EOC), fallopian tube cancer(FTC), or primary peritoneal cancer (PPC) when no more than two prior cytotoxic regimenshave been used; due to concerns for gastrointestinal perforation. We sought to determinebevacizumab-related toxicities in heavily pretreated recurrent EOC. Methods: We performed a retrospective chart review of patients with recurrent EOC, FTC,and PPC from 2001 to 2011. Patients who received at least two prior chemotherapy regimensbefore bevacizumab were included. Medical records were reviewed for bevacizumabassociated toxicities. The Wilcoxon-Mann-Whitney test was used to compare quantitativevariables. Survival was estimated with the Kaplan-Meier method. Results: Sixty patients met inclusion criteria. At the start of bevacizumab treatment, themedian age was 60 years and the median body mass index was 26.5 kg/m2. More than 50%of patients received bevacizumab after three prior cytotoxic regimens. Grade 3 or higherbevacizumab associated toxicity events occurred in four patients, including one patient whodeveloped a rectovaginal fistula. The median overall survival from the start of bevacizumabtreatment was 21.05 months (95% CI, 18.23 to 32.67; range, 1.9 to 110 months). The numberof cytotoxic regimens prior to bevacizumab treatment did not differ in those that experienceda toxicity versus those that did not (p=0.66). Conclusion: The use of bevacizumab in heavily pretreated EOC, FTC, or PPC is worthconsideration.
-
Chirag A. Shah,Tiffany Beck,John B. Liao,Nadia V. Giannakopoulos,Dan Veljovich,Pam Paley 대한부인종양학회 2017 Journal of Gynecologic Oncology Vol.28 No.6
Objective: The use of robotic radical hysterectomy has greatly increased in the treatment of early stage cervical cancer. We sought to compare surgical and oncologic outcomes of women undergoing robotic radical hysterectomy compared to open radical hysterectomy. Methods: The clinic-pathologic, treatment, and recurrence data were abstracted through an Institutional Review Board-approved protocol at 2 separate large tertiary care centers in Seattle, Swedish Medical Center and the University of Washington. Data were collected from 2001–2012. Comparisons between the robotic and open cohorts were made for complications, recurrence, progression-free survival (PFS), and overall survival (OS). Results: In the study period, 109 robotic radical hysterectomies were performed. These were compared to 202 open radical hysterectomies. The groups were comparable in terms of age and body mass index (BMI). Length of stay (LOS) was considerably shorter in the robotic group (42.7 vs. 112.6 hours, p<0.001) as was estimated blood loss (EBL; 105.9 vs. 482.6 mL, p<0.001). There were more complications in the open radical hysterectomy group, 23.4% vs. 9.2% in the robotic group (p=0.002). The recurrence rate was comparable between the groups (10.1% vs. 10.4%, p=0.730). In multivariate adjusted analysis, robotic surgery was not a statistically significant predictor of PFS (p=0.230) or OS (0.85). Conclusion: Our study, one of the largest multi-institution cohorts of patients undergoing robotic radical hysterectomy, suggest robotic radical hysterectomy leads to comparable oncologic outcomes in the treatment of early stage cervical cancer with improved short-term surgical outcomes such as decreased LOS and EBL.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
